Drug profile · INN
tafamidis
VYNDAMAX
tafamidis (VYNDAMAX) is a transthyretin stabiliser. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — tafamidis
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
tafamidis (VYNDAMAX) is a transthyretin stabiliser. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Transthyretin stabiliser
Primary target: Transthyretin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tafamidis?
tafamidis (VYNDAMAX) is a transthyretin stabiliser. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tafamidis?
VYNDAMAX is a marketed brand name for tafamidis. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tafamidis?
tafamidis has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.